Ken Bartizal, Chief Development Officer at Trius Therapeutics Inc (TSRX), sold 2,000 shares at $7.90 ($16K) on 2013-06-04, disclosed to the SEC on 2013-06-04.
Scheduled sale ($16k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TSRX | SELL | 2013-05-28 | $95K | — | Filing → |
| TSRX | SELL | 2011-11-18 | $13K | — | Filing → |